-- 上海復星医薬（上海証券取引所：600196、香港証券取引所：2196）傘下の復星凱ロス（上海）生物技術が、中国国家薬品監督管理局からFKC289注射剤の第I/II相臨床試験の承認を取得したことが、火曜日に香港証券取引所に提出された書類で明らかになった。 この薬剤は、原発性軽鎖アミロイドーシスおよび膜性腎症の治療薬として試験される。 同社は、条件が満たされ次第、試験を開始する予定である。
Related Articles
Asia
Easou Technology Invests $7.7 Million in Wealth Product Using Idle Top-up Placing Funds
Easou Technology (HKG:2550) said it has subscribed to a $7.7 million wealth management product issued by Huatai International Financial Products, using idle proceeds from its earlier placings, according to a Friday Hong Kong bourse filing.Shares of the digital service firm were down over 1% in Monday's late-morning trade.The investment, guaranteed by Huatai International Financial, carries an annualized return of 1.07% to 5.83% over a term ending March 30, 2027.Easou said the move aims to enhance the utilization efficiency and returns on idle funds while maintaining liquidity.
$HKG:2550
Asia
SSY Group Gets Chinese Regulatory Nod for Production, Registration of Two Products
SSY Group (HKG:2005) said it received Chinese regulatory approval to begin drug production and registration of its diltiazem hydrochloride in injection form, according to a Hong Kong bourse filing Monday.The drug is mainly used to treat a heart condition known as supraventricular tachycardia and the emergency treatment of abnormally high blood pressure during surgery.The firm's propranolol hydrochloride injection was also approved for production and registration by China's National Medical Products Administration.The product is mainly used to treat supraventricular tachyarrhythmias and ventricular arrhythmias.
$HKG:2005
Asia
Amplitude Energy Says Australian Retirement Trust Raises Stake
Amplitude Energy (ASX:AEL) said Australian Retirement Trust raised its stake in the firm to 6.3% as of Friday from 5.1% as of April 2, according to a Monday Australian bourse filing.Australian Retirement Trust now holds nearly 19 million votes in the firm.
$ASX:AEL